{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T11:48:20Z","timestamp":1765885700554},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2009,8,21]],"date-time":"2009-08-21T00:00:00Z","timestamp":1250812800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1007\/s12032-009-9289-6","type":"journal-article","created":{"date-parts":[[2009,8,20]],"date-time":"2009-08-20T16:13:07Z","timestamp":1250784787000},"page":"807-814","source":"Crossref","is-referenced-by-count":7,"title":["Management of venous thromboembolism in colorectal cancer patients treated with bevacizumab"],"prefix":"10.1007","volume":"27","author":[{"given":"Mitsukuni","family":"Suenaga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Mizunuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kokoro","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiji","family":"Shinozaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Matsusaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisho","family":"Chin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasutoshi","family":"Kuboki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Ichimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Ozaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariko","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshimasa","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Matsueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumio","family":"Konishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyohiko","family":"Hatake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,8,21]]},"reference":[{"key":"9289_CR1","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1200\/JCO.2005.05.112","volume":"23","author":"FF Kabbinavar","year":"2005","unstructured":"Kabbinavar FF, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol. 2005;23:3697\u2013705.","journal-title":"J Clin Oncol"},{"key":"9289_CR2","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1200\/JCO.2003.10.066","volume":"21","author":"F Kabbinavar","year":"2003","unstructured":"Kabbinavar F, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)\/leucovorin (LV) with FU\/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003;21:60\u20135.","journal-title":"J Clin Oncol"},{"key":"9289_CR3","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, et al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335\u201342.","journal-title":"N Engl J Med"},{"key":"9289_CR4","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1200\/JCO.2006.09.6305","volume":"25","author":"BJ Giantonio","year":"2007","unstructured":"Giantonio BJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25:1539\u201344.","journal-title":"J Clin Oncol"},{"issue":"June 20 Supplem","key":"9289_CR5","doi-asserted-by":"crossref","first-page":"4036","DOI":"10.1200\/jco.2007.25.18_suppl.4036","volume":"25","author":"A Grothey","year":"2007","unstructured":"Grothey A, et al. Association between exposure to bevacizumab (BV) beyond first progression (BBP) and overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): results from a large observational study (BRiTE). J Clin Oncol. 2007;25(June 20 Supplement):4036. (Abstract).","journal-title":"J Clin Oncol"},{"key":"9289_CR6","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1093\/jnci\/djm086","volume":"99","author":"FA Scappaticci","year":"2007","unstructured":"Scappaticci FA, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 2007;99:1232\u20139.","journal-title":"J Natl Cancer Inst"},{"issue":"19","key":"9289_CR7","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1001\/jama.2008.656","volume":"300","author":"SR Nalluri","year":"2008","unstructured":"Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA. 2008;300(19):2277\u201385.","journal-title":"JAMA"},{"key":"9289_CR8","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1200\/JCO.2005.03.5600","volume":"24","author":"AY Lee","year":"2006","unstructured":"Lee AY, et al. Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. J Clin Oncol. 2006;24:1404\u20138.","journal-title":"J Clin Oncol"},{"key":"9289_CR9","doi-asserted-by":"crossref","first-page":"3665","DOI":"10.1200\/JCO.2003.08.008","volume":"21","author":"M Verso","year":"2003","unstructured":"Verso M, Agnelli G. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol. 2003;21:3665\u201375.","journal-title":"J Clin Oncol"},{"key":"9289_CR10","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1055\/s-0038-1648912","volume":"72","author":"M Montr\u00e9al","year":"1994","unstructured":"Montr\u00e9al M, et al. Pulmonary embolism in patients with upper extremity DVT associated to venous central lines: a prospective study. Thromb Haemost. 1994;72:548\u201350.","journal-title":"Thromb Haemost"},{"key":"9289_CR11","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1093\/annonc\/mdl431","volume":"18","author":"D Fagnani","year":"2007","unstructured":"Fagnani D, et al. Thrombosis-related complications and mortality in cancer patients with central venous devices: an observational study on the effect of antithrombotic prophylaxis. Ann Oncol. 2007;18:551\u20135.","journal-title":"Ann Oncol"},{"key":"9289_CR12","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1200\/JCO.2005.10.192","volume":"23","author":"S Couban","year":"2005","unstructured":"Couban S, et al. Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol. 2005;23:4063\u20139.","journal-title":"J Clin Oncol"},{"key":"9289_CR13","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1093\/annonc\/mdj059","volume":"17","author":"M Karthaus","year":"2006","unstructured":"Karthaus M, et al. Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. Ann Oncol. 2006;17:289\u201396.","journal-title":"Ann Oncol"},{"key":"9289_CR14","doi-asserted-by":"crossref","first-page":"5490","DOI":"10.1200\/JCO.2007.14.1283","volume":"25","author":"AA Khorana","year":"2007","unstructured":"Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007;25:5490\u2013505.","journal-title":"J Clin Oncol"},{"key":"9289_CR15","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","volume":"5","author":"AA Khorana","year":"2007","unstructured":"Khorana AA, Francis CW, Culakova E. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5:632\u20134.","journal-title":"J Thromb Haemost"},{"key":"9289_CR16","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1001\/archinte.160.6.809","volume":"160","author":"JA Heit","year":"2000","unstructured":"Heit JA, et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000;160:809\u201315.","journal-title":"Arch Intern Med"},{"key":"9289_CR17","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1200\/JCO.2005.05.098","volume":"23","author":"KD Miller","year":"2005","unstructured":"Miller KD, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005;23:792\u20139.","journal-title":"J Clin Oncol"},{"key":"9289_CR18","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1200\/JCO.2004.11.022","volume":"22","author":"DH Johnson","year":"2004","unstructured":"Johnson DH, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004;22:2184\u201391.","journal-title":"J Clin Oncol"},{"key":"9289_CR19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/annonc\/mdm272","volume":"19","author":"S Vescia","year":"2008","unstructured":"Vescia S, et al. Management of venous port systems in oncology: a review of current evidence. Ann Oncol. 2008;19:9\u201315.","journal-title":"Ann Oncol"},{"key":"9289_CR20","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/BF00366902","volume":"1","author":"KA Newman","year":"1993","unstructured":"Newman KA, Reed WP, Schimpff SC, Bustamante CI, Wade JC. Hickman catheters in association with intensive cancer chemotherapy. Support Care Cancer. 1993;1:92\u20137.","journal-title":"Support Care Cancer"},{"key":"9289_CR21","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1002\/1097-0142(19921001)70:7<1895::AID-CNCR2820700715>3.0.CO;2-I","volume":"70","author":"PE Drakos","year":"1992","unstructured":"Drakos PE, et al. Low molecular weight heparin for Hickman catheter-induced thrombosis in thrombocytopenic patients undergoing bone marrow transplantation. Cancer. 1992;70:1895\u20138.","journal-title":"Cancer"},{"key":"9289_CR22","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1002\/1097-0142(19831101)52:9<1586::AID-CNCR2820520908>3.0.CO;2-4","volume":"52","author":"JJ Lokich","year":"1983","unstructured":"Lokich JJ, Becker B. Subclavian vein thrombosis in patients treated with infusion chemotherapy for advanced malignancy. Cancer. 1983;52:1586\u20139.","journal-title":"Cancer"},{"key":"9289_CR23","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1111\/j.1445-2197.1995.tb00563.x","volume":"65","author":"C Koksoy","year":"1995","unstructured":"Koksoy C, Kuzu A, Erden I, Akkaya A. The risk factors in central venous catheter-related thrombosis. Aust NZ J Surg. 1995;65:796\u20138.","journal-title":"Aust NZ J Surg"},{"key":"9289_CR24","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/j.1365-2141.2005.05529.x","volume":"129","author":"A Cortelezzi","year":"2005","unstructured":"Cortelezzi A, et al. Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective, multicenter study. Br J Haematol. 2005;129:811\u20137.","journal-title":"Br J Haematol"},{"key":"9289_CR25","doi-asserted-by":"crossref","first-page":"4057","DOI":"10.1200\/JCO.2005.06.084","volume":"23","author":"M Verso","year":"2005","unstructured":"Verso M, et al. Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. J Clin Oncol. 2005;23:4057\u201362.","journal-title":"J Clin Oncol"},{"key":"9289_CR26","unstructured":"Berry S et al. Lack of effect of starting bevacizumab shortly after venous access device implantation on wound healing\/bleeding complications: preliminary results from first BEAT. ASCO Gastrointestinal Cancer Symposia 2006. San Francisco, CA; January 26\u201328, 2006. p. 245 (Abstract)."},{"key":"9289_CR27","doi-asserted-by":"crossref","first-page":"4036","DOI":"10.1200\/jco.2007.25.18_suppl.4036","volume":"172s","author":"A Grothey","year":"2007","unstructured":"Grothey A, et al. Association between exposure to bevacizumab beyond first progression and overall survival in patients with metastatic colorectal cancer: Results from a large observational study (BRiTE). Proc Am Soc Clin Oncol. 2007;172s:4036. (Abstract).","journal-title":"Proc Am Soc Clin Oncol"},{"key":"9289_CR28","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1200\/jco.2007.25.18_suppl.4028","volume":"170s","author":"L Saltz","year":"2007","unstructured":"Saltz L, et al. Bevacizumab in combination with XELOX or FOLFOX: Updated efficacy results from XELOX-1\/N016966, a randomized phase III trial in first line metastatic colorectal cancer. Proc Am Soc Clin Oncol. 2007;170s:4028. (Abstract).","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"19","key":"9289_CR29","first-page":"f173","volume":"114","author":"K Barnard","year":"2006","unstructured":"Barnard K. Viewpoint: an explanation for the cardiovascular effects of bevacizumab and rofecoxib? Circulation. 2006;114(19):f173\u20135.","journal-title":"Circulation"},{"issue":"6","key":"9289_CR30","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1161\/01.ATV.20.6.1512","volume":"20","author":"I Zachary","year":"2000","unstructured":"Zachary I, Mathur A, Yla-Herttuala S, Martin J. Vascular protection: a novel nonangiogenic cardiovascular role for vascular endothelial growth factor. Arterioscler Thromb Vasc Biol. 2000;20(6):1512\u201320.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"9289_CR31","first-page":"1445","volume":"152","author":"NN Nissen","year":"1998","unstructured":"Nissen NN, et al. Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing. Am J Pathol. 1998;152(6):1445\u201352.","journal-title":"Am J Pathol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-009-9289-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-009-9289-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-009-9289-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T15:54:28Z","timestamp":1590076468000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-009-9289-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8,21]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["9289"],"URL":"https:\/\/doi.org\/10.1007\/s12032-009-9289-6","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,8,21]]}}}